Treatment of Cystic Fibrosis with CFTR Modulators;Therapie der Mukoviszidose mit CFTR-Modulatoren

Pneumologie

Volumn 70, Issue 5, 2016, Pages 301-313

  Tummler B ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CFTR PROTEIN, HUMAN; CHLORIDE CHANNEL STIMULATING AGENT; DRUG COMBINATION; GENETIC MARKER; LUMACAFTOR, IVACAFTOR DRUG COMBINATION; QUINOLONE DERIVATIVE; TUMOR MARKER;

ARTICLE; BIOASSAY; CYSTIC FIBROSIS; GENE MUTATION; GERMANY; HUMAN; POPULATION GENETICS; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; PERSONALIZED MEDICINE; PROCEDURES; TREATMENT OUTCOME;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; BIOMARKERS, TUMOR; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; EVIDENCE-BASED MEDICINE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PRECISION MEDICINE; QUINOLONES; TREATMENT OUTCOME;

EID: 84959055667     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0042-100607     Document Type: Article

References (64)

1. Ratjen F., Bell S. C., Rowe S. M. et al. Cystic fibrosis. Nature Dis Primers: 2015; 15010
2. Mall M. A., Elborn J. S. Hrsg. Cystic Fibrosis. ERS monograph 64. Wakefield, UK Charlesworth Press: 2014
3. Sens B., Stern M. Hrsg. Qualitätssicherung Mukoviszidose 2011. Bad Honnef Hippocampus: 2012
4. Tümmler B. Hrsg. Mutation-specific therapies in cystic fibrosis - Current status and prospects. Bremen Uni-Med: 2014
5. Riordan J. R. CFTR function and prospects for therapy. Annu Rev Biochem: 2008; 77 701 726
6. Gibson L. E., Cooke R. E. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics: 1959; 23 545 549
7. Sato K., Sato F. Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro. J Clin Invest: 1984; 73 1763 1771
8. Quinton P., Molyneux L., Ip W. et al. β-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med: 2012; 186 732 739
9. Knowles M., Gatzy J., Boucher R. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J Clin Invest: 1983; 71 1410 1417
10. Rowe S. M., Clancy J. P., Wilschanski M. Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol: 2011; 741 69 86
11. Wilschanski M., Famini H., Strauss-Liviatan N. et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J: 2001; 17 1208 1215
12. Sermet-Gaudelus I., Girodon E., Sands D. et al. Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. Am J Respir Crit Care Med: 2010; 182 929 936
13. De Jonge H. R., Ballmann M., Veeze H. et al. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros: 2004; 03 02 159 163
14. Mall M., Hirtz S., Gonska T. et al. Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J Cyst Fibros: 2004; 03 02 165 169
15. Derichs N., Sanz J., Von Kanel T. et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax: 2010; 65 594 599
16. Dekkers J. F., Wiegerinck C. L., de Jonge H. R. et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med: 2013; 19 939 945
17. Eckford P. D., Ramjeesingh M., Molinski S. et al. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol: 2014; 21 666 678
18. Linde L., Kerem B. Nonsense-mediated mRNA decay and cystic fibrosis. Methods Mol Biol: 2011; 741 137 154
19. Fan-Minogue H., Bedwell D. M. Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity. RNA: 2008; 14 148 157
20. Lee H. L., Dougherty J. P. Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol Ther: 2012; 136 227 266
21. Kerem E., Hirawat S., Armoni S. et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet: 2008; 372 719 727
22. Sermet-Gaudelus I., Boeck K. D., Casimir G. J. et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med: 2010; 182 1262 1272
23. Kerem E., Konstan M. W., De Boeck K. et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med: 2014; 2 539 547
24. Moran O., Zegarra-Moran O. A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein. FEBS Lett: 2005; 579 3979 3983
25. Van Goor F., Hadida S., Grootenhuis P. D. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A: 2009; 106 18825 18830
26. Eckford P. D., Li C., Ramjeesingh M. et al. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem: 2012; 287 36639 36649
27. Yu H., Burton B., Huang C. J. et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros: 2012; 11 237 245
28. Van Goor F., Yu H., Burton B. et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros: 2014; 13 29 36
29. Accurso F. J., Rowe S. M., Clancy J. P. et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med: 2010; 363 1991 2003
30. Ramsey B. W., Davies J., McElvaney N. G. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med: 2011; 365 1663 1672
31. Davies J. C., Wainwright C. E., Canny G. J. et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med: 2013; 187 1219 1225
32. Davies J., Sheridan H., Bell N. et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med: 2013; 1 630 638
33. Harrison M. J., Murphy D. M., Plant B. J. Ivacaftor in a G551D homozygote with cystic fibrosis. N Engl J Med: 2013; 369 1280 1282
34. Hebestreit H., Sauer-Heilborn A., Fischer R. et al. Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation. J Cyst Fibros: 2013; 12 599 603
35. Graeber S. Y., Hug M. J., Sommerburg O. et al. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. Am J Respir Crit Care Med: 2015; 192 1252 1255
36. Rowe S. M., Heltshe S. L., Gonska T. et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med: 2014; 190 175 184
37. De Boeck K., Munck A., Walker S. et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros: 2014; 13 674 680
38. Moss R. B., Flume P. A., Elborn J. S. et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med: 2015; 3 524 533
39. Kälin N., Claass A., Sommer M. et al. DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis. J Clin Invest: 1999; 103 1379 1389
40. van Barneveld A., Stanke F., Tamm S. et al. Functional analysis of F508del CFTR in native human colon. Biochim Biophys Acta: 2010; 1802 1062 1069
41. Okiyoneda T., Veit G., Dekkers J. F. et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol: 2013; 9 444 454
42. Van Goor F., Hadida S., Grootenhuis P. D. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A: 2011; 108 18843 18848
43. Clancy J. P., Rowe S. M., Accurso F. J. et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax: 2012; 67 12 18
44. Boyle M. P., Bell S. C., Konstan M. W. et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med: 2014; 2 527 538
45. Wainwright C. E., Elborn J. S., Ramsey B. W. et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med: 2015; 373 220 231
46. He L., Kota P., Aleksandrov A. A. et al. Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J: 2013; 27 536 545
47. Davis P. B. Another Beginning for Cystic Fibrosis Therapy. N Engl J Med: 2015; 373 274 276
48. Jones A. M., Barry P. J. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Thorax: 2015; 70 615 616
49. Tümmler B. The stony road to phe508del CFTR pharmacotherapy: smoothing the first rock. Lancet Respir Med: 2014; 2 508 509
50. Wainwright C. E. Ivacaftor for patients with cystic fibrosis. Expert Rev Respir Med: 2014; 8 533 538
51. Pankow S., Bamberger C., Calzolari D. et al. δF508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature: 2015; 528 510 516
52. Phuan P. W., Veit G., Tan J. et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol: 2014; 86 42 51
53. Veit G., Oliver K., Apaja P. M. et al. Ribosomal stalk silencing corrects the ΔF508-CFTR functional expression defect. PLoS Biology: 2016; [im Druck]
54. Roth D. M., Hutt D. M., Tong J. et al. Modulation of the maladaptive stress response to manage diseases of protein folding. PLoS Biol: 2014; 12 e1001998
55. De Stefano D., Villella V. R., Esposito S. et al. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy: 2014; 10 2053 2074
56. Cholon D. M., Quinney N. L., Fulcher M. L. et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med: 2014; 6 246ra96
57. Veit G., Avramescu R. G., Perdomo D. et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med: 2014; 6 246ra97
58. Phuan P. W., Veit G., Tan J. A. et al. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action. Mol Pharmacol: 2015; 88 791 799
59. Brinks V., Lipinska K., Koppelaar M. et al. QR-010 treatment for cystic fibrosis: Assessing the airway - mucus barrier in delivery. Ped Pulmonol: 2015; 50 41 271
60. Leuchte H. H., Behr J., Ewert R. et al. Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension. Pneumologie: 2015; 69 135 143
61. Taylor-Cousar J. L., Zemanick E., Salomon G. The pharmacokinetics of N9115, an inhibitor of S-nitrosoglutathione reductase, in cystic fibrosis patients. Ped Pulmonol: 2015; 50 41 285 286
62. Dörk T., Dworniczak B., Aulehla-Scholz C. et al. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet: 1997; 100 365 377
63. Quittner A. L., Buu A., Messer M. A. et al. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest: 2005; 128 2347 2354
64. Rowe S. M., Liu B., Hill A. et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One: 2013; 8 e66955